Skip to main content
Equibles
TMDX logo

TMDX · TransMedics Group, Inc. · Documents

Track TMDX — free

Use TMDX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TMDX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$91.38 -0.62 (-0.67%) At close · Nov 13 Play latest call Q1 2026 earnings call transcript
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$3.17B
Shares
34.73M
Volume · Nov 13 840.86K Avg daily vol (3M) 894.64K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $605.49M up 37.1% 10-K filed Feb 24, 2026 Quarterly report FY2026 Q3 Revenue $203.01M up 41.1% 10-Q filed Nov 5, 2026 Latest results Strong revenue growth drives higher guidance 8-K filed Nov 5, 2026 Earnings call Q1 2026 earnings call Held May 5, 2026
2026
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue growth outpaced profit as expenses rose

TransMedics Group, Inc. generated total revenue of $566.9 million and net income of $39.1 million for the nine months ended September 30, 2026, while research, development, clinical trials and administrative expenses increased.

Revenue $203.01M ▲ 41.1% Net income $17.07M ▼ 29.8% Diluted EPS $0.46 ▼ 30.3%
Read from the MD&A section
3 source passages
We generated total revenue of $203.0 million and $566.9 million, and net income of $17.1 million and $39.1 million, for the three and nine months ended September 30, 2026, respectively. Total research, development and clinical trials expenses increased by $37.3 million from $48.4 million in the nine months ended September 30, 2025 to $85.7 million in the nine months ended September 30, 2026. Total selling, general and administrative expenses increased by $48.4 million from $133.7 million in the nine months ended September 30, 2025 to $182.1 million in the nine months ended September 30, 2026. Open the document at this passage
Nov 5
Current report 8-K
Strong revenue growth drives higher guidance

TransMedics Group, Inc. reported third-quarter revenue of $203.0 million, up 41%, net income of $17.1 million and raised full-year 2026 revenue guidance to $764-$774 million, including approximately $14 million from PAD Aviation.

Financial results
4 source passages
TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended September 30, 2026. - Total revenue of $203.0 million, up 41%, including organic revenue growth* of 35% - Net income of $17.1 million or $0.46 per diluted share in the third quarter of 2026 - Raises full-year 2026 revenue guidance to between $764-$774 million, inclusive of approximately $14 million from PAD Aviation Open the document at this passage
Aug 4
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $189.95M ▲ 20.7% Net income $14.68M ▼ 57.9% Diluted EPS $0.41 ▼ 55.4%
May 5
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $173.93M ▲ 21.2% Net income $7.32M ▼ 71.5% Diluted EPS $0.20 ▼ 71.4%
Apr 10
Proxy statement DEF 14A Meeting May 20, 2026
Proxy statement AI summary on its way
Feb 24
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $605.49M ▲ 37.1% Net income $190.29M ▲ 436.6% Diluted EPS $4.87 ▲ 382.2%
2025
Oct 29
Quarterly report 10-Q FY2025 Q3, ended Sep 30
Quarterly report for FY2025 Q3
Revenue $143.82M ▲ 32.2% Net income $24.32M ▲ 476.8% Diluted EPS $0.66 ▲ 450.0%
Jul 30
Quarterly report 10-Q FY2025 Q2, ended Jun 30
Quarterly report for FY2025 Q2
Revenue $157.37M ▲ 37.7% Net income $34.91M ▲ 186.3% Diluted EPS $0.92 ▲ 162.9%
May 8
Quarterly report 10-Q FY2025 Q1, ended Mar 31
Quarterly report for FY2025 Q1
Revenue $143.54M ▲ 48.2% Net income $25.68M ▲ 110.6% Diluted EPS $0.70 ▲ 100.0%
Feb 27
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $441.54M ▲ 82.7% Net income $35.46M Diluted EPS $1.01
2024
Showing 1–50 of 159 documents
Key facts CIK 1756262 CUSIP 89377M109 13F (30d) 311 filings 274 filers Visit website Investor relations